Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialGeorgina V. Long, Matteo S. Carlino, Andrew Hill et al.|The Lancet Oncology|2017Cited by 247
Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.Georgina V. Long, Matteo S. Carlino, Victoria Atkinson et al.|Journal of Clinical Oncology|2016Cited by 48
Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohortGeorgina V. Long, John A. Thompson, Atkinson et al.|Unknown|2016Cited by 8